application abstract): Drug-resistant malaria is an important emerging disease and new strategies to control this problem are urgently needed. This project will involve the study of in vivo and in vitro antimalarial drug resistance in Uganda. It will be used as a pilot for subsequent larger studies designed to identify molecular markers of drug-resistant malaria. In this study, a series of patients presenting with falciparum malaria at Mulago Hospital, Kampala, Uganda will be studied. The clinical responses of patients to standard therapy with chloroquine will be correlated with measurements of the in vitro sensitivity of their malarial isolates, with the presence of mutations in critical genes in infecting parasites, and with the presence of host genetic polymorphisms that may impact on responses to drug-resistant malaria.
The specific aims of the project are designed to test the hypotheses that in vitro antimalarial drug resistance patterns can predict clinical drug resistance in a heterogeneous African population, that specific parasite mutations can predict drug resistance, and that certain host mutations may alter the clinical course of drug-resistant malaria.
These specific aims are (1) to correlate in vitro drug resistance with clinical responses to antimalarial therapy, (2) to correlate drug resistance with mutations in Plasmodium genes that may mediate resistance, and (3) to correlate clinical outcomes during drug-sensitive and drug-resistant malaria infections with host genetic polymorphisms. These studies should help define the extent of in vitro and clinical resistance to antimalarial drugs in Kampala, a previously under-studied site, allow the evaluation of resistance progression over time, provide information on our ability to use in vitro data to predict clinical responses in a heterogeneous population, and test the contributions of parasite and host genetic polymorphisms in antimalarial drug resistance. The long-term goals of the study are to develop a mechanism for tracking antimalarial drug resistance in Uganda and to identify molecular markers of clinically relevant drug resistance. Such markers should significantly aid in the study, and eventually the therapy and control of drug-resistant malaria in Africa.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI043301-02
Application #
2887769
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Fairfield, Alexandra
Project Start
1998-09-30
Project End
2001-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Gantt, Soren; Huang, Meei-Li; Magaret, Amalia et al. (2013) An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 58:276-8
Staedke, Sarah G; Jagannathan, Prasanna; Yeka, Adoke et al. (2008) Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 7:107
Hwang, Jimee; Bitarakwate, Edward; Pai, Madhukar et al. (2006) Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Trop Med Int Health 11:789-99
Slater, Madeline; Kiggundu, Moses; Dokomajilar, Chris et al. (2005) Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg 73:256-62
Dorsey, Grant; Gasasira, Anne F; Machekano, Rhoderick et al. (2004) The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am J Trop Med Hyg 71:531-6
Dorsey, Grant; Dokomajilar, Christian; Kiggundu, Moses et al. (2004) Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg 71:758-63
Nsobya, Sammuel L; Parikh, Sunil; Kironde, Fred et al. (2004) Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J Infect Dis 189:2220-6
Staedke, Sarah G; Mpimbaza, Arthur; Kamya, Moses R et al. (2004) Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 364:1950-7
Staedke, Sarah G; Sendagire, Hakim; Lamola, Steven et al. (2004) Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health 9:624-9
Njama-Meya, Denise; Kamya, Moses R; Dorsey, Grant (2004) Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 9:862-8

Showing the most recent 10 out of 17 publications